Acquisition of syncytium-inducing HIV-1 strains during therapy with zidovudine alone or combined with alpha interferon or didanosine

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 4, 1996, Pages 324-327

  Torres, Y ^a   Leal, M ^a   Rey, C ^a   Medrano, F J ^a   Sanchez Quijano A ^a   Lissen, E ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; DIDANOSINE; ZIDOVUDINE;

ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; GIANT CELLS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; MALE; PHENOTYPE; PROSPECTIVE STUDIES; ZIDOVUDINE;

EID: 0029972949     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01695665     Document Type: Article

References (12)

1. Koot M, Keet IPM, Vos AHV, De Goede REY, Ross MTL, Coutinho RA, Miedema F, Schellekens PTA, Tersmette M: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Annals of Internal Medicine 1993, 118: 681-688.
2. Buckheit RW, Germany-Decker J, Qualls-Goodwin K, Bowdon BJ, Shannon WM: 3′-azido-3′-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation. Proceedings of the National Academy of Sciences of the USA 1992, 89: 8361-8365.
3. Bozzette SA, McCutchan JA, Spector SA, Wright B, Richman DD: A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. Journal of Infectious Diseases 1993, 168: 1374-1379.
4. Boucher CAB, Lange JMA, Miedema F, Weverling GJ, Koot M, Mulder JW, Goudsmidt J, Kellam P, Larder BA, Tersmette M: HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992, 6: 1259-1264.
5. Koot M, Schellekens PTA, Mulder JW, Lange JMA, Roos MTL, Coutinho RA, Tersmette M, Miedema F: Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. Journal of Infectious Diseases 1993, 168: 733-736.
6. Leal M, Torres Y, Medrano FJ, Calderon EJ, Rey C, Lissen E: Does early zidovudine treatment prevent the emergence of syncytium-inducing human immunodeficiency virus? Journal of Infectious Diseases 1994, 170: 1041.
7. Delforge ML, Liesnard C, Debaisieux M, Tchetcheroff M, Farber CM, Van Vooren JP: In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. AIDS 1995, 9: 89-101.
8. Schellekens PTA, Tersmette M, Roos MTL, Keet RP, de Wolf F, Coutinho RA, Miedema F: Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS 1992, 6: 665-669.
9. Richman DD, Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. Journal of Infectious Diseases 1994, 169: 968-974.
10. Karlsson A, Parsmyr K, Sandström E, Fenyö EM, Albert J: MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. Journal of Clinical Microbiology 1994, 32: 364-370.
11. Koot M, Vos AHV, Keet RPM, Goede REY, Dercksen MW, Terpstra FG, Coutinho RA, Miedema F, Tersmette M: HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992, 6: 49-54.
12. Karlsson A, Parsmyr K, Aperia K, Sandström E, Fenyö EM, Albert J: MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. Journal of Infectious Diseases 1994, 170: 1367-1375.